Recently, Zelixir Biotech announced the completion of a funding round exceeding 100 million yuan, establishing itself as a pioneer in the industry by reconstructing the entire process of synthetic biology through AI technology. The funds raised in this round will be used to strengthen research and development efforts and drive the construction of the company's synthetic biology pipeline.

According to reports, following this funding round, Zelixir Biotech will further deepen the integration of "AI+ Synthetic Biology" in four dimensions: technology, platform, pipeline, and team. Firstly, they will enhance their unique and industry-leading AI technology capabilities. Secondly, they will accelerate the integration of AI technology throughout the entire process, from design and synthesis to testing and learning, to create a new generation of AI-driven synthetic biology platform. Thirdly, they plan to expand their existing product pipeline based on this new platform and facilitate rapid product development. Lastly, they will focus on establishing production facilities and expanding their team of talents.

Zelixir Biotech, founded in 2021, was initiated by a team of experts in the field of molecular structure prediction, design algorithms, and synthetic biology experiments, who have rich experience from renowned academic institutions and industrial backgrounds. The company aims to reconstruct the entire process of synthetic biology through AI and biocomputing methods, including reaction pathway design, discovery, design and modification of related biological components, and automated high-throughput intelligent research and development and production. Their goal is to achieve significant cost reduction, improved efficiency, and rapid commercialization of products. Currently, the company possesses competitive AI technology capabilities and synthetic biology industry expertise.

The core team of the company is composed of experts with doctoral degrees and extensive experience in AI computing and synthetic biology. The team members have received international recognition and prestigious awards in their respective fields, demonstrating outstanding academic achievements and influence. In terms of AI computing, Dr. Wang Sheng, a leading figure in the company, was selected as one of the "Top 2% Scientists Globally" by Stanford University in 2022. In the same year, Zelixir Biotech team achieved remarkable results in the 15th edition of the Critical Assessment of Protein Structure Prediction (CASP), known as the "Olympics" of the field, ranking first in RNA structure prediction and second in protein-small molecule complex prediction, standing out in the global industry.

In the field of synthetic biology, Zelixir Biotech has assembled a team with deep expertise and practical experience in the synthetic biology industry. The team has previously produced various synthetic biology products at kilogram and ton scales in the field of metabolic fermentation engineering.

Currently, Zelixir Biotech is continuously pushing the boundaries of biotechnology through AI technology, combining known data mining with the creation of design tools to empower various stages of synthetic biology, including DBTL (Design, Build, Test, Learn) and scale-up production, to achieve cost reduction and efficiency improvement. Through building their own product pipeline and collaboration with the industry, they are driving the development of the medical and health, agriculture, food, consumer, and chemical industries together.

Disclaimer: Despite our efforts to maintain accuracy, errors are unavoidable due to our limited expertise. Some information may not be up to date, and we welcome your feedback to make necessary corrections. This document is intended solely for the purpose of providing a business-oriented and written introduction to the field of synthetic biology. It does not constitute any investment advice. We appreciate your understanding.